American Enterprise Institute (AEI) economist  Roger Bate shares his expertise on counterfeit drug networks that pose a growing threat to combating diseases like malaria.

U.S. military training missions are an economical way to promote security and good governance and to support our friends and allies and prepare them to tackle these problems on their own, as well as help other countries in the region. 

In an attempt to protect poor, uninsured and underinsured Americans from unsafe drugs, we are making sure that some go without drugs completely. It is time the law was changed.

In a just-published op-ed in the New York Times, American Enterprise Institute (AEI) international health economist Roger Bate highlights a better way to fight fake pharmaceuticals while still giving poor Americans access to less costly drugs from online pharmacies.

Knowing where all our ingredients come from is the first step toward improving drug quality.

Today, URL Pharma was acquired by Takeda for nearly $800M.  The story here in brief is that for hundreds of years, colchicine was used for the treatment of gout and other conditions; it was an effective drug but had to be used carefully. URL invested in the formulation development and clinical studies required for colchicine, and ultimately received FDA approval in 2009. 

Every day patients receive treatments that do not work properly. For many this means no relief from symptoms, but for some death is the result. Yet concerted action against such products is limited. Before we can discuss why that's the case, I will attempt to explain what kind of products don’t work, and what we should call them.